Recently, three insiders made the requisite Form 4 filings with the U.S. Securities and Exchange Commission, indicating that Mark Schwartz, Chairman and CEO, had purchased 100,000 shares; Larry Leitner, director, had purchased 100,000 shares; and Alan Stern, director, had purchased 42,500 shares.

“The fact that three insiders purchased shares at prices in excess of upcoming warrant exercise prices indicates the strong belief in the underlying potential of the Company’s stock,” said Mark Schwartz. “Insider buying speaks volumes,” he continued.

Hypertension Diagnostics, Inc. strives to save lives by reducing the risk of cardiovascular disease using the CVProfilor^®. The CVProfilor measures the elasticity of small and large arteries, a key indicator of cardiovascular health. More information is available at www.hdii.com.

Forward-looking statements in this press release are made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The Company wishes to caution readers not to place undue reliance on any forward-looking statements and to recognize that the statements are not a prediction of actual future results. Actual results could differ materially from those presented and anticipated in the forward-looking statements due to the risks and uncertainties set forth in the Company’s 2004 Annual Report on Form 10-KSB, and the subsequent Quarterly Report on Form 10-QSB, which were filed with the U.S. Securities and Exchange Commission, as well as others not now anticipated.

CVProfilor is a registered trademark of Hypertension Diagnostics, Inc.

Hypertension Diagnostics, HDI/PulseWave, PulseWave and CVProfile are trademarks of Hypertension Diagnostics, Inc. All rights reserved.

Website: www.HDII.com
 
Contact: Mark Schwartz, CEO
651-687-9999